Impact of Erg11 amino acid substitutions identified in *Candida auris* clade III isolates on triazole drug susceptibility

Benjamin Williamson¹, Adam Wilk¹, Kevin D. Guerrero², Timothy D. Mikulski², Tony N. Elias², Indira Sawh¹, Geselle Cancino-Prado¹, Dianne Gardam³, Christopher H. Heath^{3,4,5,6}, Nelesh P. Govender^{7,8,9}, David S. Perlin², Milena Kordalewska^{2*}, and Kelley R. Healey^{1*}

¹William Paterson University, Department of Biology, 300 Pompton Road, Wayne, NJ, USA 07470

²Center for Discovery and Innovation, Hackensack Meridian Health, 111 Ideation Way, Nutley, NJ, USA 07110

³ Department of Microbiology, PathWest Laboratory Medicine FSH Network, Fiona Stanley Hospital, Murdoch, Western Australia (WA), Australia

⁴ Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, Australia

⁵ Infectious Diseases, Royal Perth Hospital, Perth, WA, Australia

⁶ Faculty of Health & Medical Sciences, University of Western Australia, Crawley, WA, Australia

⁷ Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Sandringham 2131, South Africa

⁸ School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Parktown 2193, South Africa

⁹ MRC Centre for Medical Mycology, University of Exeter, Exeter, EX4 4PY, United Kingdom

*Address correspondence to Kelley R. Healey, healeyk3@wpunj.edu or Milena Kordalewska, milena.kordalewska@hnh-cdi.org

Running title: Analysis of *Candida auris* clade III *ERG11* mutations

Keywords: *Candida auris*; *ERG11*; triazole resistance; fluconazole resistance; clade III; African clade; heterologous expression; mutagenesis; short- and long-tailed triazoles

Abstract

ERG11 sequencing of 28 *Candida auris* clade III isolates revealed the presence of concomitant V125A and F126L substitutions. Heterologous expression of Erg11-V125A/F126L in *Saccharomyces cerevisiae* led to reduced fluconazole and voriconazole susceptibilities. Generation of single substitution gene variants through site-directed mutagenesis uncovered that F126L primarily contributes to the elevated triazole MICs. A similar, yet diminished pattern of reduced susceptibility was observed with long-tailed triazoles posaconazole and itraconazole for V125A/F126L, F126L, Y132F, and K143R alleles.

Text

Candida auris is an emerging fungal pathogen that has spread across the globe and caused multiple healthcare center outbreaks. Strains of *C. auris* are divided into five genetically-distinct, geographic clades: South Asian (I), East Asian (II), African (III), South American (IV), and Iranian (V) (1). Initial spread of *C. auris* to the U.S. and other parts of the world is predicted to have occurred through multiple travel-related introductions (2). Recently, several reports have shown high rates of *C. auris* candidemia in hospitalized patients with severe COVID-19 (SARS-CoV-2 virus) infection, particularly in severely ill patients in the ICU setting (3-5). Interestingly, the pathogenicity of *C. auris* differs from other species in that it can colonize the skin, persist on hospital surfaces and medical equipment, and transfer from person to person (6, 7). In addition, *C. auris* exhibits elevated rates of antifungal resistance. Clinical isolates that demonstrate reduced susceptibility to one or more classes of antifungals, including triazoles, polyenes

(amphotericin B), and echinocandins, have been reported, with triazole resistance being the most prevalent (8-10).

Triazole antifungals (e.g. fluconazole, voriconazole, itraconazole, posaconazole) target the biosynthesis of fungal ergosterol, specifically through inhibition of lanosterol 14- α -demethylase (Erg11p) that is encoded by the *ERG11* gene in yeast. Early reports identified single Erg11 substitutions (F126L, Y132F, or K143R) in strains from multiple clades (9, 11-13). These substitutions were highlighted due to their connection to triazole resistance within other species of *Candida*, specifically *C. albicans* (14). In our previous study (15), we identified and analyzed *C. auris* *ERG11* mutations in clinical isolates of clade I and IV. Using a heterologous expression system, we directly linked Y132F and K143R Erg11 substitutions to fluconazole and voriconazole resistance; whereas, other alterations (e.g. I466M, Y501H, and clade-specific polymorphisms) were not associated with elevated minimum inhibitory concentrations (MICs).

Here, we investigated triazole resistance in 28 clinical isolates of *C. auris* clade III obtained from South Africa (n=21), Australia (n=5), and the CDC and FDA Antimicrobial Resistance (AR) Isolate Bank (n=2). *ERG11* was amplified and sequenced as described before (15). In agreement with recent reports (8, 16, 17), we identified two *ERG11* mutations, T374C and T376C, that lead to two amino acid substitutions, V125A and F126L, respectively, in all 28 isolates (**Table 1**). Antifungal susceptibility testing was performed according to CLSI methodology (18, 19) and MICs were interpreted using tentative breakpoints as suggested by the CDC (<https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html>). These isolates demonstrated reduced triazole susceptibilities, specifically to fluconazole and voriconazole (**Table 1**). Of note, three clinical isolates (SA 13, 15, and 16) demonstrated fluconazole MICs in the susceptible range (< 32 μ g/ml), despite containing the same *ERG11* mutations as the other strains (**Table 1**). This may point to additional alterations in these isolates that specifically influence the fluconazole-Erg11p interaction. Further analyses on these strains are underway.

Using the same approach as in (15), we cloned the Erg11 allele (V125A/F126L) from isolate AR-0384 onto a low-copy plasmid (pRS416), which was then expressed in a haploid strain of *S. cerevisiae* (BY4741). This heterologous system allowed us to focus solely on the effects of *ERG11* mutations on triazole susceptibilities. Multiple clones were passaged on selective medium (synthetic defined medium lacking uracil; SD-Ura), screened by PCR, and resulting plasmid sequences verified (for primers, see (15)). *S. cerevisiae* that expressed *C. auris* Erg11-V125A/F126L demonstrated elevated MICs to fluconazole (64 µg/ml) and voriconazole (1 µg/ml). In comparison, expression of an empty vector or Erg11-wild type alleles from other clades yielded MICs 4 to 8-fold more susceptible (≤ 16 µg/ml to fluconazole; ≤ 0.25 µg/ml to voriconazole) (**Table 2**).

To further dissect the specific role of V125A and F126L substitutions in triazole resistance, we designed mutagenic primers to individually revert each amino acid substitution (**Figure 1**). A Phusion site-directed mutagenesis kit (Thermo Scientific, MA, USA) was used to introduce the desired wild-type mutations. The resulting *C. auris* Erg11-V125A and Erg11-F126L plasmid constructs were expressed in *S. cerevisiae*. In addition, we performed two consecutive rounds of site-directed mutagenesis to produce a strain that carried neither substitution (Erg11-V125/F126) (**Figure 1D-E**). This strain represented a *de facto* clade III wild-type allele. Plasmid sequences of all alleles were confirmed. Subsequent triazole susceptibility assays revealed that cells expressing F126L alone exhibited elevated MICs similar in levels to V125A/F126L, while V125A alone led to MICs similar to the wild-type alleles (**Table 2**). Our engineered, clade III wild-type allele yielded susceptible MICs, allowing us to conclude that the *ERG11* mutations, as opposed to expression levels, were mainly contributing to the observed decreased susceptibility.

Drug binding and cloning studies have demonstrated that certain *ERG11* mutations in *S. cerevisiae* and *C. albicans* influence susceptibility to all triazoles, while other mutations lead to decreased susceptibility to only short- or long- tailed triazoles (20-22). Therefore, in addition to

fluconazole and voriconazole (short-tailed triazoles), we tested all of our strains to determine susceptibility to posaconazole and itraconazole (long-tailed triazoles) (**Table 2**). Changes in posaconazole and itraconazole MICs were minimal, although consistent, with 2 to 4-fold differences between the “resistant” alleles (V125A/F126L, Y132F, or K143R) and wild type alleles (**Table 2**). These results are in alignment with the minimal differences observed in clinical isolates (**Table 1**) and to those of previous studies that analyzed Y132F and K143R (or equivalent changes) in *C. albicans* and *S. cerevisiae* (21, 23).

Crystallization of *C. albicans* Erg11 identified residue 126 (and the equivalent residue in *S. cerevisiae*) as being located within the enzyme’s active site and a likely player in substrate binding (24, 25). Furthermore, the authors from this study predicted that alteration of this residue would likely reduce affinity for all triazole drugs but would do so most extensively for short-tailed azoles (24). Since all *C. auris* clade III isolates described in the literature contain both V125A and F126L substitutions, it is likely that these two mutations occurred at nearly the same time in the evolution of this clade. The V125A substitution may simply be a passenger mutation. Alternatively, V125A may increase the stability of the Erg11 enzyme or be advantageous for the yeast in another way and/or in combination with other alterations (e.g., *ERG11* copy number variants (8)). Studies have since identified *TAC1b* transcription factor mutations, linked to increased expression of drug efflux pumps (e.g., *CDR1* and/or other unidentified transporters), as an alternate mechanism of triazole resistance in *C. auris* (26-28). Additionally, a recent report demonstrated an additive effect that concomitant *ERG11* (F444L) and *TAC1b* mutations can have on triazole susceptibility (29).

In conclusion, the *ERG11* allele found in *C. auris* clade III isolates directly contributes to reduced triazole susceptibility, in particular to fluconazole and voriconazole. Moreover, our mutagenic experiments revealed that the F126L substitution was primarily responsible for the elevated triazole MICs. Results of this study further improve our understanding of triazole

resistance mechanisms in *C. auris* which can have a direct impact on diagnostic and treatment practices.

Acknowledgments

This research was supported by William Paterson University (WPU) Department of Biology and College of Science and Health's Center for Research to K.R.H. Undergraduate work of B.W. and A.W. was supported by WPU College of Science and Health and of I.S. and G.C.-P. by the NSF Louis Stokes Alliances for Minority Participation (LSAMP) program. The authors declare no potential conflicts of interest related to this work.

References

1. Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. 2020. *Candida auris*: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog 16:e1008921.
2. Chow NA, Gade L, Tsay SV, Forsberg K, Greenko JA, Southwick KL, Barrett PM, Kerins JL, Lockhart SR, Chiller TM, Litvintseva AP, Team USCal. 2018. Multiple introductions and subsequent transmission of multidrug-resistant *Candida auris* in the USA: a molecular epidemiological survey. Lancet Infect Dis 18:1377-1384.
3. Chowdhary A, Tarai B, Singh A, Sharma A. 2020. Multidrug-Resistant *Candida auris* Infections in Critically Ill Coronavirus Disease Patients, India, April-July 2020. Emerg Infect Dis 26:2694-2696.
4. Villanueva-Lozano H, Trevino-Rangel RJ, Gonzalez GM, Ramirez-Elizondo MT, Lara-Medrano R, Aleman-Bocanegra MC, Guajardo-Lara CE, Gaona-Chavez N, Castilleja-Leal F, Torre-Amione G, Martinez-Resendez MF. 2021. Outbreak of *Candida auris* infection in a COVID-19 hospital in Mexico. Clin Microbiol Infect doi:10.1016/j.cmi.2020.12.030.

5. Prestel C, Anderson E, Forsberg K, Lyman M, de Perio MA, Kuhar D, Edwards K, Rivera M, Shugart A, Walters M, Dotson NQ. 2021. *Candida auris* Outbreak in a COVID-19 Specialty Care Unit - Florida, July-August 2020. MMWR Morb Mortal Wkly Rep 70:56-57.
6. de Jong AW, Hagen F. 2019. Attack, Defend and Persist: How the Fungal Pathogen *Candida auris* was Able to Emerge Globally in Healthcare Environments. Mycopathologia 184:353-365.
7. Sexton DJ, Bentz ML, Welsh RM, Derado G, Furin W, Rose LJ, Noble-Wang J, Pacilli M, McPherson TD, Black S, Kemble SK, Herzegh O, Ahmad A, Forsberg K, Jackson B, Litvintseva AP. 2021. Positive correlation between *Candida auris* skin-colonization burden and environmental contamination at a ventilator-capable skilled nursing facility in Chicago. Clin Infect Dis doi:10.1093/cid/ciab327.
8. Chow NA, Munoz JF, Gade L, Berkow EL, Li X, Welsh RM, Forsberg K, Lockhart SR, Adam R, Alanio A, Alastruey-Izquierdo A, Althawadi S, Arauz AB, Ben-Ami R, Bharat A, Calvo B, Desnos-Ollivier M, Escandon P, Gardam D, Gunturu R, Heath CH, Kurzai O, Martin R, Litvintseva AP, Cuomo CA. 2020. Tracing the Evolutionary History and Global Expansion of *Candida auris* Using Population Genomic Analyses. mBio 11.
9. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Colombo AL, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE, Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T, Litvintseva AP. 2017. Simultaneous Emergence of Multidrug-Resistant *Candida auris* on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clin Infect Dis 64:134-140.
10. Lyman M, Forsberg K, Reuben J, Dang T, Free R, Seagle EE, Sexton DJ, Soda E, Jones H, Hawkins D, Anderson A, Bassett J, Lockhart SR, Merengwa E, Iyengar P, Jackson BR, Chiller T. 2021. Notes from the Field: Transmission of Pan-Resistant and

- Echinocandin-Resistant *Candida auris* in Health Care Facilities - Texas and the District of Columbia, January-April 2021. MMWR Morb Mortal Wkly Rep 70:1022-1023.
11. Rhodes J, Abdolrasouli A, Farrer RA, Cuomo CA, Aanensen DM, Armstrong-James D, Fisher MC, Schelenz S. 2018. Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen *Candida auris*. Emerg Microbes Infect 7:43.
12. Munoz JF, Gade L, Chow NA, Loparev VN, Juieng P, Berkow EL, Farrer RA, Litvintseva AP, Cuomo CA. 2018. Genomic insights into multidrug-resistance, mating and virulence in *Candida auris* and related emerging species. Nat Commun 9:5346.
13. Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, Tarai B, Singh A, Upadhyaya G, Upadhyay S, Yadav P, Singh PK, Khillan V, Sachdeva N, Perlin DS, Meis JF. 2018. A multicentre study of antifungal susceptibility patterns among 350 *Candida auris* isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother 73:891-899.
14. Flowers SA, Colon B, Whaley SG, Schuler MA, Rogers PD. 2015. Contribution of clinically derived mutations in *ERG11* to azole resistance in *Candida albicans*. Antimicrob Agents Chemother 59:450-60.
15. Healey KR, Kordalewska M, Jimenez Ortigosa C, Singh A, Berrio I, Chowdhary A, Perlin DS. 2018. Limited ERG11 Mutations Identified in Isolates of *Candida auris* Directly Contribute to Reduced Azole Susceptibility. Antimicrob Agents Chemother 62.
16. Maphanga TG, Naicker SD, Kwenda S, Munoz JF, van Schalkwyk E, Wadula J, Nana T, Ismail A, Coetzee J, Govind C, Mtshali PS, Mpembe RS, Govender NP, for G-S. 2021. In-vitro antifungal resistance of *Candida auris* isolates from bloodstream infections, South Africa. Antimicrob Agents Chemother doi:10.1128/AAC.00517-21:AAC0051721.
17. Naicker SD, Maphanga TG, Chow NA, Allam M, Kwenda S, Ismail A, Govender NPfG-SA. 2021. Clade distribution of *Candida auris* in South Africa using whole genome sequencing of clinical and environmental isolates. Emerg Microbes Infect 10:1300-1308.

18. CLSI. 2017. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. 4th Ed. Clinical and Laboratory Standards Institute document M27.
19. CLSI. 2020. Performance Standards for Antifungal Susceptibility Testing of Yeasts. CLSI supplement M60. 2nd Ed. Clinical and Laboratory Standards Institute.
20. Sagatova AA, Keniya MV, Wilson RK, Sabherwal M, Tyndall JD, Monk BC. 2016. Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14alpha-demethylase. *Sci Rep* 6:26213.
21. Xiang MJ, Liu JY, Ni PH, Wang S, Shi C, Wei B, Ni YX, Ge HL. 2013. Erg11 mutations associated with azole resistance in clinical isolates of *Candida albicans*. *FEMS Yeast Res* 13:386-93.
22. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM. 2004. Application of real-time quantitative PCR to molecular analysis of *Candida albicans* strains exhibiting reduced susceptibility to azoles. *Antimicrob Agents Chemother* 48:2124-31.
23. Sanglard D, Ischer F, Koymans L, Bille J. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant *Candida albicans* clinical isolates contribute to resistance to azole antifungal agents. *Antimicrob Agents Chemother* 42:241-53.
24. Keniya MV, Sabherwal M, Wilson RK, Woods MA, Sagatova AA, Tyndall JDA, Monk BC. 2018. Crystal Structures of Full-Length Lanosterol 14alpha-Demethylases of Prominent Fungal Pathogens *Candida albicans* and *Candida glabrata* Provide Tools for Antifungal Discovery. *Antimicrob Agents Chemother* 62.
25. Sagatova AA, Keniya MV, Wilson RK, Monk BC, Tyndall JD. 2015. Structural Insights into Binding of the Antifungal Drug Fluconazole to *Saccharomyces cerevisiae* Lanosterol 14alpha-Demethylase. *Antimicrob Agents Chemother* 59:4982-9.

26. Rybak JM, Doorley LA, Nishimoto AT, Barker KS, Palmer GE, Rogers PD. 2019. Abrogation of Triazole Resistance upon Deletion of CDR1 in a Clinical Isolate of *Candida auris*. Antimicrob Agents Chemother 63.
27. Rybak JM, Munoz JF, Barker KS, Parker JE, Esquivel BD, Berkow EL, Lockhart SR, Gade L, Palmer GE, White TC, Kelly SL, Cuomo CA, Rogers PD. 2020. Mutations in TAC1B: a Novel Genetic Determinant of Clinical Fluconazole Resistance in *Candida auris*. mBio 11.
28. Mayr EM, Ramirez-Zavala B, Kruger I, Morschhauser J. 2020. A Zinc Cluster Transcription Factor Contributes to the Intrinsic Fluconazole Resistance of *Candida auris*. mSphere 5.
29. Li J, Coste AT, Liechti M, Bachmann D, Sanglard D, Lamothe F. 2021. Novel ERG11 and TAC1b mutations associated with azole resistance in *Candida auris*. Antimicrob Agents Chemother doi:10.1128/AAC.02663-20.

Table 1. Triazole drug susceptibility and Erg11 profiles of 28 *C. auris* clinical isolates of clade III.

Origin	Isolate*	Specimen	Erg11	FLC	MIC [†] (µg/ml)		
					VRC	POS	ITC
AR Bank	AR-0381	N/A	WT	4	0.03	<0.03	0.03
	AR-0382	N/A	WT	4	0.03	0.06	0.06
South Africa	AR-0383	N/A	V125A/F126L	>128	1	0.03	0.125
	AR-0384	N/A	V125A/F126L	>128	1	0.06	0.25
	SA1	CVC tip	V125A/F126L	>128	1	0.125	0.25
	SA2	Blood	V125A/F126L	>128	0.5	0.125	0.5
	SA3	CVC tip	V125A/F126L	>128	1	0.03	0.5
	SA4	Blood	V125A/F126L	>128	1	0.03	0.5
	SA5	Tracheal aspirate	V125A/F126L	>128	2	0.03	0.5
	SA6	Blood	V125A/F126L	>128	1	0.03	0.5
	SA7	Urine	V125A/F126L	>128	1	0.125	0.5
	SA8	Urine	V125A/F126L	>128	1	0.03	0.25
	SA9	Urine	V125A/F126L	>128	1	0.03	0.5
	SA10	Blood	V125A/F126L	>128	1	0.125	0.5
	SA11	Blood	V125A/F126L	>128	1	0.03	1
	SA12	Urine	V125A/F126L	>128	1	0.03	0.25
	SA13	Urine	V125A/F126L	8	1	0.03	0.25
	SA14	Urine	V125A/F126L	>128	2	0.03	0.5
	SA15	Tracheal aspirate	V125A/F126L	8	1	0.03	0.5
	SA16	Tracheal aspirate	V125A/F126L	8	1	0.03	0.5
	SA17	Urine	V125A/F126L	>128	1	0.03	0.25
	SA18	Urine	V125A/F126L	128	0.5	0.03	0.5
Australia	SA19	Urine	V125A/F126L	128	2	0.03	0.25
	SA22	Urine	V125A/F126L	128	0.5	0.25	0.5
	SA23	Urine	V125A/F126L	>128	8	0.25	0.5
	A3	Sternum	V125A/F126L	>128	1	0.25	1
	A4	Sternum	V125A/F126L	>128	1	0.25	1
	A6	Axilla & Groin	V125A/F126L	>128	0.25	0.125	1
	A7	Axilla & Groin	V125A/F126L	>128	0.25	0.25	1
	A8	Catheter specimen of urine (CSU)	V125A/F126L	>128	0.5	0.25	1

*For reference, susceptibility results are presented for two Erg11 wild-type (WT) strains: AR-0381 (clade II) and AR-0382 (clade I).

[†]FLC, fluconazole; VRC; voriconazole; POS, posaconazole; ITC, itraconazole.

Table 2. Triazole susceptibilities of *S. cerevisiae* strains that express *C. auris* Erg11 plasmid constructs.

Erg11 allele	MIC* (µg/ml)		POS	ITC
	FLC	VRC		
Empty vector	16	0.12	0.25	0.5
wild type (clade I)	16	0.25	0.25	1
wild type (clade IV)	16	0.12	0.25	1
I466M	16	0.25	0.5	2
Y132F	128	2	0.5	4
K143R	64	1	0.5	2
V125A/F126L	64	1	0.5	2
wild type (clade III)	16	0.25	0.25	1
V125A	16	0.25	0.25	1
F126L	64	1	0.5	4

*MICs are representative of three independent experiments and obtained in both nutrient-rich YPD (Yeast extract, Peptone, Dextrose) (MICs displayed) and nutrient-limited SD-Ura broth media; we observed a 2-fold or less difference between media. Fluconazole and voriconazole MICs of the first six strains were previously reported (15); however, these MICs were repeated in tandem with the newly engineered strains and are presented here for comparison. FLC, fluconazole; VRC, voriconazole; POS, posaconazole; ITC, itraconazole.

A.

Erg11-V125A/F126L

...364 acc act cca gCt Ctc ggg aaa ggt gtc att tac gac tgt 402...
...122 T T P A L G K G V I Y D C 134...

B.

Erg11-V125A only

5' act cca gCt Ttc ggg aaa ggt gtc att 3'
... T P A F G K G V I ...

C.

Erg11-F126L only

5' act cca gTt Ctc ggg aaa ggt gtc att t 3'
... T P V L G K G V I ...

D.

Erg11-'wild type'

5' act cca gTt Ttc ggg aaa ggt gtc att 3'
... T P V F G K G V I ...

E.

Figure 1. Molecular dissection of *C. auris* Erg11 V125A and F126L amino acid substitutions.

A, Region of clade III *ERG11* DNA that displays nucleotide mutations (T374C/T376C) in red and resulting protein alterations (V125A/F126L) in yellow highlight. **B**, Forward mutagenic primer used to revert Leucine (L) back to Phenylalanine (F). After mutagenesis, this construct contained only V125A (pCauErg11-V125A). **C**, Forward mutagenic primer used to revert Alanine (A) back to wild type Valine (V). After mutagenesis, this construct contained only F126L

312 (pCauErg11-F126L). **D**, Forward mutagenic primer used to revert Leucine (L) back to
 313 Phenylalanine (F) using the pCauErg11-F126L plasmid as a template. After mutagenesis, this
 314 construct contained both wild type nucleotides and amino acids (pCauErg11-‘wt’). **E**, Plasmid
 315 sequencing chromatograms of relevant codons corresponding to the 125th and 126th amino
 316 acids following mutagenesis and propagation in *E. coli*.
 317
 318